Transgenomic licenses exclusive rights to multiplexed ICE COLD-PCR technology Transgenomic announced that it has signed a license with the Dana-Farber Cancer Institute for worldwide rights to develop and commercialize multiplexed versions of its ICE COLD-PCR technology. The new license is exclusive to Transgenomic and expands the current relationship with Dana-Farber. It covers all fields and applications of the multiplexed technology, which makes possible the simultaneous detection of multiple DNA mutations from a single liquid sample, such as blood or urine.
Transgenomic, University of Melbourne announce collaboration Transgenomic announced a research agreement with the University of Melbourne to conduct additional clinical validation studies of its Multiplexed ICE COLD-PCRTM technology. The new study will be conducted using DNA isolated from pre-treatment tumor biopsies from patients enrolled in clinical trials. It aims to determine the prevalence and clinical significance of ultra-low frequency mutations that would otherwise go undetected by NGS or Sanger sequencing-based methodologies. In the next phase of the project, Transgenomic expects to conduct further studies with University of Melbourne researchers to validate the use of MX-ICP to accurately detect tumor mutations using blood or plasma. Transgenomic’s MX ICE COLD-PCR technology is exclusively licensed from the Dana-Farber Cancer Institute.